Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02433834 · ClinicalTrials.gov registry record · Phase 2
Chronic Dosing Cross-Over Study to Assess the Efficacy and Safety of Glycopyrronium (PT001) in Adult Subjects With Intermittent Asthma or Mild to Moderate Persistent Asthma
A Phase 2 study, sponsored by Pearl Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 248
- Enrollment target
NCT02433834 is a Phase 2 study that has completed, run by Pearl Therapeutics. The registered enrollment target is 248 participants.
The verdict
NCT02433834, a Phase 2 study, has completed, sponsored by Pearl Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 248 participants
- Enrollment target
Study Summary
A Randomized, Double-Blind, Chronic Dosing (14 days), 5-Period, 7-Treatment, Placebo-Controlled, Incomplete Block, Cross-Over, Multi-center, Dose-ranging Study to Assess the Efficacy and Safety of Glycopyrronium MDI (PT001) Relative to Placebo MDI and Open-Label Serevent Diskus in Adult Subjects With Intermittent Asthma or Mild to Moderate Persistent Asthma
Interventions
- DRUG Placebo
- DRUG Glycopyrronium MDI
- DRUG Serevent Diskus 50 μg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 248 participants |
| Start Date | 2015-05-27 |
| Est. Completion | 2016-03-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02433834
The ClinicalTrials.gov registry entry for NCT02433834 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 248 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pearl Therapeutics, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02433834 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02433834 about?
NCT02433834 is a clinical study titled "Chronic Dosing Cross-Over Study to Assess the Efficacy and Safety of Glycopyrronium (PT001) in Adult Subjects With Intermittent Asthma or Mild to Moderate Persistent Asthma". A Randomized, Double-Blind, Chronic Dosing (14 days), 5-Period, 7-Treatment, Placebo-Controlled, Incomplete Block, Cross-Over, Multi-center, Dose-ranging Study to Assess the Efficacy and Safety of Glycopyrronium MDI (PT001) Relative to Placebo MDI and Open-Label Serevent Diskus in Adult Subjects Wit...
What is the current status of trial NCT02433834?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 248 participants. The study started on 2015-05-27. Estimated completion is 2016-03-26.
What interventions are being tested in trial NCT02433834?
The interventions under investigation include: Placebo (DRUG), Glycopyrronium MDI (DRUG), Serevent Diskus 50 μg (DRUG).
Who is sponsoring clinical trial NCT02433834?
This trial is sponsored by Pearl Therapeutics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.